


NaveniBright™ PD1/PD-L1 BOND RX

ILLUMINATING FUNCTION IN SPATIAL PROTEOMICS

Automated detection of PD1/PD-L1 interactions *in situ*

Immune checkpoint therapy (ICT) responses can vary among patients, underscoring the need for improved predictive biomarkers to refine patient stratification. Although PD-L1 immunohistochemistry (IHC) is widely used, the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear[1]. Preliminary data show that the PD1/PD-L1 interaction may be a predictive biomarker for ICT response in NSCLC, providing more information than the current clinical standard of PD-L1 IHC[2]. Now, Navinci introduces the NaveniBright™ PD1/PD-L1 BOND RX in collaboration with Leica Biosystems for enhanced reproducibility and throughput.

NaveniBright™ PD1/PD-L1 BOND RX enables you to:




- Visualize the precise interaction of PD1/PD-L1 within the tissue microenvironment.
- Evaluate the potential of PD1/PD-L1 interaction as a biomarker with a high throughput automated kit.
- Achieve heightened efficiency and reproducibility through an automated workflow, streamlining your research process.
- Save valuable time with the automated workflow, minimizing hands-on time and maximizing productivity.

In partnership with Leica Biosystems

For additional information and images,
read more on navinci.se/technology/naveni-bond


Navinci

Version 1.0 DOC-0059




How it works

The NaveniBright™ PD1/PD-L1 BOND RX kit uses the Naveni® *in situ* proximity ligation technology. It includes primary antibodies and Navenibodies (orange in the illustration). When in close proximity, they trigger a rolling circle amplification reaction, creating a strong, distinct dot. Optimized for the BOND RX Fully Automated Research Stainer, the kit has been rigorously verified across diverse FFPE tissues and three research sites, ensuring robust performance.



PD1/PD-L1 interaction in head and neck cancer, Squamous cell carcinoma.



PD1/PD-L1 interaction in germinal centers, lymph node.

Available from Navinci

Catalog nr	Kit	Target	Description
60031	NaveniBright BOND RX	Your choice, use primary antibodies with host origin of mouse and rabbit	Anti-mouse Navenibody Anti-rabbit Navenibody Buffers for blocking and dilutions and detection reagents Reagents sufficient for 30 FFPE tissue slides, including dead volumes*
60032	NaveniBright PD1/PD-L1 BOND RX	Human PD1/PD-L1 interaction	Navenibody targeting human PD1 protein based on clone EH33 CST Navenibody targeting human PD-L1 protein based on clone SP142 Abcam RabMAb® Buffers for blocking and dilutions and detection reagents for the PD1/PD-L1 interaction signal Reagents sufficient for 30 FFPE tissue slides, including dead volumes*

*additional reagents required, read more on navinci.se/technology/naveni-bond
Research use only, not for use in diagnostic procedures

1) Sánchez-Magraner L, et al., High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Res 80, 19 (2020)
2) Micke P, et al., PD1-PDL1 interaction as a superior predictor for response to immune checkpoint therapy in NSCLC patients. AACR 2024 7-10 April; San Diego (CA); Abstract nr 5139

Leica BIOSYSTEMS **In partnership with Leica Biosystems**

Navinci